- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07504120
Vliv vzdáleně poskytovaného pilates na fyzické a psychologické výsledky u osob s roztroušenou sklerózou (MS)
Ovlivňuje vzdáleně poskytované pilates fyzické a psychické výsledky u osob s roztroušenou sklerózou?
Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.
Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.
Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
The current study will determine the feasibility and efficacy of a 16-week remotely delivered Pilates intervention for improving physical and psychological outcomes, and QOL, compared with a control condition, in individuals with MS. This represents a significant step forward in examining Pilates as an accessible, complementary therapy in MS.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60612
- Nábor
- University of Illinois Chicago
-
Kontakt:
- Parisa Najafi, PhD
- Telefonní číslo: 7735055923
- E-mail: pems@uic.edu
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age 18 years or older
- Self-reported diagnosis of multiple sclerosis by a neurologist
- Relapse-free for the past 30 days before screening
- Able to speak and read English as the primary language
- Access to the internet and e-mail,
- Ability to use Zoom, and willingness to complete testing sessions and questionnaires
- Ambulatory without an assistive device (for example, cane)
- Low to moderate disability, defined as a score of 0-4 on the Patient-Determined Disease Steps (PDDS)
- Insufficiently active, defined as a score < 14 on the Godin Leisure-Time Exercise Questionnaire-Health Contribution Score (GLTEQ-HCS)
- Adequate visual ability and literacy to read materials printed in 14-point font
- Currently treated with a disease-modifying therapy
Exclusion Criteria:
- Pregnant
- Elevated risk for strenuous or maximal exercise, defined as more than one "Yes" response on the Physical Activity Readiness Questionnaire (PAR-Q) during screening
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Jiný: Pilates group
Behavioral: Pilates group |
REMOTLY PILATES EXERCISE |
|
Žádný zásah: Control group
Waitlist Group |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in walking endurance (Six-Minute Walk Test distance)
Časové okno: Baseline and 16 weeks (end of treatment)
|
Distance walked during the Six-Minute Walk Test (6MWT) will be measured in meters. The outcome is the change from baseline to 16 weeks in 6MWT distance. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in walking speed (Timed 25-Foot Walk)
Časové okno: Baseline and 16 weeks (end of treatment)
|
Walking speed will be assessed using the Timed 25-Foot Walk (T25FW). The outcome is the change from baseline to 16 weeks in time to walk 25 feet, measured in seconds. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in balance (Berg Balance Scale)
Časové okno: Baseline and 16 weeks (end of treatment)
|
Balance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure of static and dynamic balance. Each item is scored from 0 to 4, and the outcome will be the change from baseline to 16 weeks in the BBS total score (range 0-56), with higher scores indicating better balance and lower risk of falls. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in fatigue (Fatigue Severity Scale)
Časové okno: Baseline and 16 weeks (end of treatment)
|
Fatigue will be measured using the Fatigue Severity Scale (FSS), a 9-item questionnaire assessing the impact of fatigue on daily functioning. Each item is rated from 1 to 7, and the outcome will be the change from baseline to 16 weeks in the FSS mean score (range 1-7), with higher scores indicating more severe fatigue. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in pain (Short-form McGill Pain Questionnaire)
Časové okno: Baseline and 16 weeks (end of treatment)
|
Pain will be measured using the Short-form McGill Pain Questionnaire (SF-MPQ). The outcome is the change from baseline to 16 weeks in SF-MPQ total score. |
Baseline and 16 weeks (end of treatment)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in cognitive processing speed (Symbol Digit Modalities Test)
Časové okno: Baseline and 16 weeks (end of treatment)
|
Cognitive processing speed will be assessed using the Symbol Digit Modalities Test (SDMT). The outcome is the change from baseline to 16 weeks in SDMT total score, with higher scores indicating better processing speed. SDMT scores typically range from 0 to about 110 correct responses. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in verbal learning and memory (California Verbal Learning Test-II)
Časové okno: Baseline and 16 weeks (end of treatment)
|
Verbal learning and memory will be assessed using the California Verbal Learning Test-II (CVLT-II). The outcome is the change from baseline to 16 weeks in CVLT-II total recall score, with higher scores indicating better verbal learning and memory. CVLT-II total recall scores typically range from 0 to about 80. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in visuospatial learning and memory (Brief Visuospatial Memory Test-Revised)
Časové okno: Baseline and 16 weeks (end of treatment)
|
Visuospatial learning and memory will be assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). The outcome is the change from baseline to 16 weeks in BVMT-R total recall score, with higher scores indicating better visuospatial memory. BVMT-R total recall scores typically range from 0 to 36. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in depression symptoms
Časové okno: Baseline and 16 weeks (end of treatment)
|
Depression will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Depression subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in depression total score, with higher scores indicating greater depressive symptoms. Typical depression scales have ranges such as 0-21 (HADS-D) ; enter the exact range that matches the scale you are using. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in anxiety symptoms
Časové okno: Baseline and 16 weeks (end of treatment)
|
Anxiety will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Anxiety subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in anxiety total score, with higher scores indicating greater anxiety. Typical anxiety scales have ranges such as 0-21 (HADS-A) or 0-63 (BAI); enter the exact range that matches the scale you are using. |
Baseline and 16 weeks (end of treatment)
|
|
Change from baseline in health-related quality of life
Časové okno: Baseline and 16 weeks (end of treatment)
|
Health-related quality of life will be assessed using a validated questionnaire (e.g., the MSQoL-54 or a comparable instrument). The outcome is the change from baseline to 16 weeks in the quality-of-life total score or composite score. For instruments scored 0-100, higher scores typically indicate better quality of life; specify the exact scoring range and direction according to your chosen measure. |
Baseline and 16 weeks (end of treatment)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Neurologické projevy
- Nemoci nervového systému
- Autoimunitní onemocnění
- Onemocnění imunitního systému
- Symptomy chování
- Neurobehaviorální projevy
- Demyelinizační autoimunitní onemocnění, CNS
- Autoimunitní onemocnění nervového systému
- Demyelinizační onemocnění
- Poruchy vnímání
- Patologické stavy, příznaky a symptomy
- Chování
- Příznaky a symptomy
- Bolest
- Roztroušená skleróza
- Deprese
- Únava
- Agnosia
- Terapeutika
- Modality fyzikální terapie
- Techniky pohybu cvičení
Další identifikační čísla studie
- STUDY2025-0648-MOD001
- MB-2110-38597 (Jiné číslo grantu/financování: National Multiple Sclerosis Society)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .